U.S. markets close in 1 hour 44 minutes
  • S&P 500

    4,560.89
    +28.13 (+0.62%)
     
  • Dow 30

    35,219.12
    +190.47 (+0.54%)
     
  • Nasdaq

    14,454.86
    +114.60 (+0.80%)
     
  • Russell 2000

    2,083.16
    +20.37 (+0.99%)
     
  • Crude Oil

    87.15
    +0.19 (+0.22%)
     
  • Gold

    1,841.50
    -1.70 (-0.09%)
     
  • Silver

    24.68
    +0.45 (+1.85%)
     
  • EUR/USD

    1.1321
    -0.0026 (-0.23%)
     
  • 10-Yr Bond

    1.8360
    +0.0090 (+0.49%)
     
  • GBP/USD

    1.3624
    +0.0012 (+0.09%)
     
  • USD/JPY

    114.1690
    -0.1840 (-0.16%)
     
  • BTC-USD

    43,022.73
    +1,153.57 (+2.76%)
     
  • CMC Crypto 200

    1,022.99
    +27.73 (+2.79%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,772.93
    +305.70 (+1.11%)
     

NVAX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 11, 2022 in the Class Action Filed on Behalf of Novavax, Inc. Limited Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

New York, New York--(Newsfile Corp. - November 29, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Novavax, Inc. (NASDAQ: NVAX) alleging that the Company violated federal securities laws.

Class Period: March 2, 2021 to October 19, 2021
Lead Plaintiff Deadline: January 11, 2022
No obligation or cost to you.

Learn more about your recoverable losses in NVAX:
https://www.kleinstocklaw.com/pslra-1/novavax-inc-loss-submission-form-2?id=21647&from=5

Novavax, Inc. NEWS - NVAX NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Novavax, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Novavax you have until January 11, 2022 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Novavax securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the NVAX lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/105548